Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Net Cash Flow (2019 - 2025)

Harmony Biosciences Holdings' Net Cash Flow history spans 7 years, with the latest figure at $105.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 60.74% year-over-year to $105.5 million; the TTM value through Dec 2025 reached $299.5 million, up 111.9%, while the annual FY2025 figure was $299.5 million, 111.9% up from the prior year.
  • Net Cash Flow for Q4 2025 was $105.5 million at Harmony Biosciences Holdings, up from $100.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $105.5 million in Q4 2025 and bottomed at -$87.5 million in Q1 2021.
  • The 5-year median for Net Cash Flow is $26.9 million (2022), against an average of $26.2 million.
  • The largest annual shift saw Net Cash Flow tumbled 285.85% in 2021 before it soared 874.83% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $44.6 million in 2021, then plummeted by 139.37% to -$17.6 million in 2022, then grew by 26.4% to -$12.9 million in 2023, then surged by 607.89% to $65.6 million in 2024, then skyrocketed by 60.74% to $105.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Net Cash Flow are $105.5 million (Q4 2025), $100.9 million (Q3 2025), and $57.1 million (Q2 2025).